NATCOPHARM - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.9
| Stock Code | NATCOPHARM | Market Cap | 19,626 Cr. | Current Price | 1,096 ₹ | High / Low | 1,135 ₹ |
| Stock P/E | 13.1 | Book Value | 462 ₹ | Dividend Yield | 0.55 % | ROCE | 31.8 % |
| ROE | 27.5 % | Face Value | 2.00 ₹ | DMA 50 | 1,014 ₹ | DMA 200 | 945 ₹ |
| Chg in FII Hold | 2.21 % | Chg in DII Hold | 0.07 % | PAT Qtr | 107 Cr. | PAT Prev Qtr | 501 Cr. |
| RSI | 60.1 | MACD | 27.3 | Volume | 4,68,934 | Avg Vol 1Wk | 5,36,362 |
| Low price | 752 ₹ | High price | 1,135 ₹ | PEG Ratio | 0.08 | Debt to equity | 0.03 |
| 52w Index | 89.8 % | Qtr Profit Var | -14.4 % | EPS | 83.8 ₹ | Industry PE | 30.1 |
📊 Analysis: NATCOPHARM shows moderate intraday potential. Current price (₹1,096) is well above DMA 50 (₹1,014) and DMA 200 (₹945), reflecting strong trend support. RSI at 60.1 indicates bullish momentum but nearing overbought territory. MACD (27.3) confirms positive bias. Volume (4.68 lakh) is slightly below the 1-week average (5.36 lakh), suggesting weaker participation. PAT dropped sharply (₹501 Cr → ₹107 Cr), raising caution despite strong fundamentals.
💹 Optimal Buy Price: ₹1,090–1,100 if sustained above VWAP with improving volume.
🎯 Profit Exit Levels: ₹1,115 (near resistance) and ₹1,135 (52-week high).
🛑 Stop-Loss: ₹1,070 (below intraday support).
⏱️ If Already Holding: Book profits near ₹1,115–1,135 if RSI approaches 65 or momentum slows. Exit if price breaks below ₹1,070 with rising sell volume.
Positive
- Strong ROE (27.5%) and ROCE (31.8%) highlight efficiency.
- Low debt-to-equity (0.03) ensures financial stability.
- EPS of ₹83.8 supports valuation comfort.
- FII holding increased (+2.21%), showing foreign confidence.
- PEG ratio (0.08) indicates undervaluation relative to growth.
Limitation
- Quarterly PAT fell sharply (₹501 Cr → ₹107 Cr).
- Volume weaker than average, limiting intraday momentum.
- DII holding only marginally increased (+0.07%).
Company Negative News
- Quarterly profit decline (-14.4%) raises earnings concerns.
Company Positive News
- FII stake increased significantly (+2.21%), boosting sentiment.
- Strong long-term fundamentals with high ROE and ROCE.
Industry
- Industry P/E at 30.1 is higher than NATCOPHARM’s 13.1, suggesting undervaluation.
- Pharma sector remains resilient with steady demand outlook.
Conclusion
⚖️ NATCOPHARM offers moderate intraday trading potential with strong fundamentals and undervaluation but faces short-term earnings pressure. Suitable for trades above ₹1,090 with profit targets near ₹1,115–1,135 and strict stop-loss at ₹1,070.